Department of General, Geriatric, Oncologic Surgery and Advanced Technologies, Center of Excellence for Technical Innovation in Surgery, University of Naples Federico II, 80131 Naples, Italy.
World J Gastroenterol. 2012 Nov 21;18(43):6216-25. doi: 10.3748/wjg.v18.i43.6216.
Barrett's esophagus is a condition resulting from chronic gastro-esophageal reflux disease with a documented risk of esophageal adenocarcinoma. Current strategies for improved survival in patients with Barrett's adenocarcinoma focus on detection of dysplasia. This can be obtained by screening programs in high-risk cohorts of patients and/or endoscopic biopsy surveillance of patients with known Barrett's esophagus (BE). Several therapies have been developed in attempts to reverse BE and reduce cancer risk. Aggressive medical management of acid reflux, lifestyle modifications, antireflux surgery, and endoscopic treatments have been recommended for many patients with BE. Whether these interventions are cost-effective or reduce mortality from esophageal cancer remains controversial. Current treatment requires combinations of endoscopic mucosal resection techniques to eliminate visible lesions followed by ablation of residual metaplastic tissue. Esophagectomy is currently indicated in multifocal high-grade neoplasia or mucosal Barrett's carcinoma which cannot be managed by endoscopic approach.
巴雷特食管是一种由慢性胃食管反流病引起的疾病,其具有食管腺癌的风险。目前,改善巴雷特腺癌患者生存的策略主要集中在检测异型增生上。这可以通过对高危患者队列进行筛查计划和/或对已知的巴雷特食管(BE)患者进行内镜活检监测来实现。已经开发了几种疗法试图逆转 BE 并降低癌症风险。对于许多 BE 患者,建议采用积极的胃酸反流药物治疗、生活方式改变、抗反流手术和内镜治疗。这些干预措施是否具有成本效益或降低食管癌死亡率仍存在争议。目前的治疗需要结合内镜黏膜切除术技术来消除可见病变,然后对残余的化生组织进行消融。食管切除术目前适用于多灶性高级别肿瘤或不能通过内镜治疗的黏膜 Barrett 癌。